October 2026 brought practical shifts for dementia caregivers: home-start treatment, stronger navigation and respite, and clearer testing rules. These changes cut clinic burden, help families remain home longer, and preview new drug-trial and care guidance. Leqembi (lecanemab-irmb) is an anti-amyloid drug for early Alzheimer's disease. GUIDE is Medicare's dementia-care model that pairs families with a navigator for coordination, education, and respite.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Can Treatment Start at Home?
- How Can Navigation and Respite Help You Stay Home?
- What Do Blood Tests and Limits Mean for Decisions?
- Where Can Late-Stage and Frontotemporal Families Turn?
- What Should You Watch Next?
Can Treatment Start at Home?
The U.S. Food and Drug Administration says it approved a weekly subcutaneous starting dose for Leqembi in July 2026 the FDA approval notice. It is the first home start instead of IV infusions.
That change cuts clinic visits and eases caregiver travel and scheduling. The Food and Drug Administration limits Leqembi and Kisunla to mild cognitive impairment or mild dementia due to Alzheimer's. MCI means early, measurable trouble with memory or thinking. Both drugs require MRI safety monitoring during treatment.
How Can Navigation and Respite Help You Stay Home?
The Centers for Medicare & Medicaid Services says its GUIDE Model launched July 1, 2024 with 390 organizations the CMS GUIDE model page. Each site pairs families with a care navigator. Navigators coordinate care, teach caregivers, and arrange respite to support staying home.
For eligible Medicare families in GUIDE, CMS materials describe up to $2,500 per year for respite such as in-home care or adult day programs, plus 24/7 support access. Traditional Medicare otherwise covers respite only under hospice. Hospice News reporting on Empath Health notes families can ask local systems about these options now:.
- Does this clinic offer GUIDE navigation and 24/7 help
- What caregiver training and respite hours fit our needs
- How does home-start dosing affect our visit plan
What Do Blood Tests and Limits Mean for Decisions?
The Alzheimer's Association released its first clinical practice guideline on blood-based biomarker tests on July 29, 2025 the AAIC guideline announcement. Blood-based biomarker tests are blood tests that detect Alzheimer's proteins. The guideline gives specialists brand-agnostic steps for testing people who already show cognitive impairment.
The Association limits this guidance to specialty review of objective impairment, not routine screening without symptoms. Anti-amyloid drugs also remain narrow in scope. Plan around both limits before seeking a test or prescription.
Where Can Late-Stage and Frontotemporal Families Turn?
The University of Kentucky Sanders-Brown Center launched CARE Compass, an online guide for later-stage dementia. It covers agitation, medical concerns, and recognizing discomfort. It also links to national groups for changing needs. California added frontotemporal degeneration, or FTD, to its neurodegenerative-disease registry after Gov.
Gavin Newsom signed Senate Bill 1047 the registry announcement. Providers must report every FTD diagnosis to public health. Separately, Hospice News reported Empath Health launched a Florida dementia program on Sept. 25, 2026 with clinician, caregiver, and first-responder education plus clinical care.
What Should You Watch Next?
The European Medicines Agency has proposed new guidance for Alzheimer's drug trials, with comments due Feb. 28, 2026. The Alzheimer's Association has signaled follow-on 2026 guidelines on staging and treatment use.
Both would shape who qualifies for testing and therapy and how clinics deliver them. Keep a short list of daily tasks you need help with, current drugs, and safety concerns. Bring that list when you ask about GUIDE navigation, respite funds, test referral, or training near you.
